Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal

Abstract
Sayana® Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject™, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP's acceptability is unknown. We measured acceptability of SP among clinic-based providers (Senegal only) and community health workers. Study design: This open-label observational study was conducted in clinics in three districts in Senegal and community-based services in two districts in Uganda. Providers administered SP to clients seeking reinjection of DMPA IM. We conducted in-depth interviews with 86 providers (52 in Senegal, 34 in Uganda) to assess their experiences providing SP to clients.
Description
Keywords
Depot medroxyprogesterone acetate (DMPA), Subcutaneous injection, Contraception, Community health worker
Citation
Burke, H. M., Mueller, M. P., Packer, C., Perry, B., Bufumbo, L., Mbengue, D., ... & Mbonye, A. (2014). Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal. Contraception, 89(5), 368-373. http://dx.doi.org/10.1016/j.contraception.2014.01.009